Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Three Organizations Form Alliance To Address Global Malnutrition
"Three internationally known organizations based in St. Louis - the Donald Danforth Plant Science Center, the Washington University School of Medicine and St. Louis Children"s Hospital" - have entered into a partnership, known as the Global Harvest Alliance (GHA), which aims to "create inexpensive, nutritionally complete food to help the world"s hungry and undernourished," the AP/Google.com reports. Alliance researchers will focus on several of the most successful approaches used to combat malnutrition and attempt to further enrich foods already used to fight it. "In addition, the alliance aims to help testing and distribution of crops genetically modified to boost nutritional content. They hope to provide the crops cheaply to farmers to produce more nutritious foods," writes the AP/Google.com (Taylor, 7/29).

Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect On Photoreceptors
Neurotech Pharmaceuticals, Inc. announced that the Company"s product candidate, NT-501, demonstrated a strong biologic effect in two Phase 2 clinical trials for retinitis pigmentosa (RP). RP is a slowly developing condition that causes the progressive degeneration of rod & cone photoreceptor cells in the retina that over time diminishes night and peripheral vision and eventually leads to blindness. RP is an orphan-designated indication for which there are currently no approved treatments.
News of the day
New Guide Explains Prosecutions For HIV Transmission
Two leading HIV charities have today launched a guide for people living with HIV in England and Wales explaining criminal prosecutions for HIV transmission.
Public Health

Boehringer Ingelheim To Present New Phase II Clinical Data On Two Lead Oncology Compounds At ASCO 2009

Clinical Science Symposium. Monday, 1 June 2009, Session Time 9:45AM - 11:15AM. # 5501 3. "Ask the Expert Online Q&A: Are the number of cancer cases increasing or decreasing in the world?" 1 April 2008. World Health Organization. 5 May 2009. http://www.who.int/features/qa/15/en/print.html. 4. Li D et al. "BIBW2992, an irreversible EGFR/HER2 inhibitor highlyeffective in preclinical lung cancer models." Oncogene 2008;27:4702-4711 5. Boehringer Ingelheim Pharmaceuticals. "BIBW 2992 and BSC Versus Placebo and BSC in Non-Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)" 23 April 2009. ClinicalTrials.gov. 5 May 2009. http://clinicaltrials.gov/ct2/show/NCT00656136?term=BIBW+2992+and+Phase+III&rank=1 6. Lynch, T. J. et al. "Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib." N. Engl. J. Med. 350, 2129-2139 (2004). Available at: http://content.nejm.org/cgi/reprint/350/21/2129.pdf. Accessed on 5 May 2009. 7. Paez, J. G. et al. "EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy." Science 304, 1497-1500 (2004). Available here. Accessed on 5 May 2009. 8. Pao, W. et al. "EGF receptor gene mutations are common in lung cancers from `never smokers` and are associated with sensitivity of tumors to gefitinib and erlotinib." Proc. Natl Acad. Sci. USA 101, 13306-13311 (2004). Available here. Accessed on 5 May 2009. 9. Riely G. J. et al. "Clinical Course of Patients with Non -Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib." Clin. Cancer Res, 12, 839-844(2006). Available at: http://clincancerres.aacrjournals.org/cgi/reprint/12/3/839. Accessed on 5 May 2009. 10. Balak, M. N. et al. "Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors." Clin. Cancer Res. 12, 6494-6500 (2006). Available at: http://clincancerres.aacrjournals.org/cgi/reprint/12/21/6494Accessed on 5 May 2009. 11. Yang C-H et al. "Phase IIb/III double-blind randomized trial of BIBW 2992, an irreversible, dual inhibitor of EGFR and HER2 plus best supportive care (BSC) versus placebo plus BSC in patients with NSCLC failing 1-2 lines of chemotherapy (CT) and erlotinib or gefitinib (LUX-Lung1): a preliminary report. General Poster Session: Lung Cancer - Metastatic." Saturday 30 May 2009, Session Time: 2:00PM - 6:00PM. # 8062 12. Hilberg F. et al. "BIBF1120 a novel, small molecule triple angiokinase inhibitor: profiling as a clinical candidate for cancer therapy." European Journal of Cancer Supplements. 2004; 2:50. 13. Lewis J. Kleinsmith. "Understanding Cancer and Related Topics: Understanding Angiogenesis." Rockville: National Cancer Institute, 2006. Available here. Accessed on 5 May 2009. 14. P Boyle and B Levin (eds). "World Cancer Report 2008.", World Health Organization: International Agency for Research on Cancer. Lyon: 2008. 15. American Cancer Society. "Cancer Facts and Figures 2008." Atlanta: 2008. Available at: http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf. Accessed on 5 May 2009. 16. American Cancer Society. "Ovarian Cancer Detailed Guide." Atlanta: 2008. Available at: http://documents.cancer.org/114.00/114.00.pdf. Accessed on 5 May 2009. Boehringer Ingelheim

Pages: 1 [2] 


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009